Eldecalcitol is a Small Molecule owned by Chugai Pharmaceutical, and is involved in 10 clinical trials, of which 9 were completed, and 1 is planned.

Eldecalcitol administration inhibits both bone resorption and formation, indicating that the increase in BMD by eldecalcitol is due to the suppression of bone resorption. This suppression was associated with the decrease in the number of osteoclasts in trabecular bone.

The revenue for Eldecalcitol is expected to reach a total of $324m through 2030. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Eldecalcitol NPV Report.

Eldecalcitol is originated and owned by Chugai Pharmaceutical.

Eldecalcitol Overview

Eldecalcitol (Edirol) is an analog of vitamin D. It is formulated as soft gelatin capsules, tablets for oral route of administration. Edirol is indicated for treatment of osteoporosis.

Eldecalcitol is under development for the treatment of osteoporosis in China. The drug candidate is a new molecular entity.

Chugai Pharmaceutical Overview

Chugai Pharmaceutical (Chugai), a subsidiary of Hoffmann-La Roche Ltd, is focused on the research, development, manufacturing, commercialization, import and export of biopharmaceuticals and therapeutic antibodies. The company offers products for the treatment of various therapeutic areas including, cancer; bone and joint diseases; renal diseases; immune disorders and infectious diseases and others. It also offers drugs to aid the kidney, liver and other organ transplants. It also has a range of product candidates in its pipeline. Operating through its network of subsidiaries, the company offers its pharmaceutical products in overseas markets including North America, Europe and Asia. Chugai is headquartered in Tokyo, Japan.

The company reported revenues of (Yen) JPY999,759 million for the fiscal year ended December 2021 (FY2021), an increase of 27% over FY2020. In FY2021, the company’s operating margin was 42.2%, compared to an operating margin of 38.3% in FY2020. In FY2021, the company recorded a net margin of 30.3%, compared to a net margin of 27.3% in FY2020. The company reported revenues of JPY225,284 million for the third quarter ended September 2022, a decrease of 4.4% over the previous quarter.

Quick View – Eldecalcitol

Report Segments
  • Innovator (NME)
Drug Name
  • Eldecalcitol
Administration Pathway
  • Oral
Therapeutic Areas
  • Musculoskeletal Disorders
Key Companies
Highest Development Stage
  • Marketed

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.